874 related articles for article (PubMed ID: 15277225)
21. Nuclear factor-kappaB is constitutively active in C-cell carcinoma and required for RET-induced transformation.
Ludwig L; Kessler H; Wagner M; Hoang-Vu C; Dralle H; Adler G; Böhm BO; Schmid RM
Cancer Res; 2001 Jun; 61(11):4526-35. PubMed ID: 11389085
[TBL] [Abstract][Full Text] [Related]
22. Oncogenic activation of the ret protooncogene in thyroid cancer.
Takahashi M
Crit Rev Oncog; 1995; 6(1):35-46. PubMed ID: 8573606
[TBL] [Abstract][Full Text] [Related]
23. Novel germline RET proto-oncogene mutations associated with medullary thyroid carcinoma (MTC): mutation analysis in Japanese patients with MTC.
Kitamura Y; Goodfellow PJ; Shimizu K; Nagahama M; Ito K; Kitagawa W; Akasu H; Takami H; Tanaka S; Wells SA
Oncogene; 1997 Jun; 14(25):3103-6. PubMed ID: 9223675
[TBL] [Abstract][Full Text] [Related]
24. Multiple endocrine neoplasia type 2B mutation in human RET oncogene induces medullary thyroid carcinoma in transgenic mice.
Acton DS; Velthuyzen D; Lips CJ; Höppener JW
Oncogene; 2000 Jun; 19(27):3121-5. PubMed ID: 10871866
[TBL] [Abstract][Full Text] [Related]
25. Glial cell line-derived neurotrophic factor differentially stimulates ret mutants associated with the multiple endocrine neoplasia type 2 syndromes and Hirschsprung's disease.
Carlomagno F; Melillo RM; Visconti R; Salvatore G; De Vita G; Lupoli G; Yu Y; Jing S; Vecchio G; Fusco A; Santoro M
Endocrinology; 1998 Aug; 139(8):3613-9. PubMed ID: 9681515
[TBL] [Abstract][Full Text] [Related]
26. Increased in vivo phosphorylation of ret tyrosine 1062 is a potential pathogenetic mechanism of multiple endocrine neoplasia type 2B.
Salvatore D; Melillo RM; Monaco C; Visconti R; Fenzi G; Vecchio G; Fusco A; Santoro M
Cancer Res; 2001 Feb; 61(4):1426-31. PubMed ID: 11245446
[TBL] [Abstract][Full Text] [Related]
27. RET/PTC1 oncogene signaling in PC Cl 3 thyroid cells requires the small GTP-binding protein Rho.
Barone MV; Sepe L; Melillo RM; Mineo A; Santelli G; Monaco C; Castellone MD; Tramontano D; Fusco A; Santoro M
Oncogene; 2001 Oct; 20(48):6973-82. PubMed ID: 11704822
[TBL] [Abstract][Full Text] [Related]
28. Medullary Thyroid Carcinoma Associated with Germline RET
Xu JY; Grubbs EG; Waguespack SG; Jimenez C; Gagel RF; Sosa JA; Sellin RV; Dadu R; Hu MI; Trotter CS; Jackson M; Rich TA; Hyde SM; Sherman SI; Cote GJ
Thyroid; 2016 Dec; 26(12):1744-1751. PubMed ID: 27673361
[TBL] [Abstract][Full Text] [Related]
29. DUSP6/MKP3 is overexpressed in papillary and poorly differentiated thyroid carcinoma and contributes to neoplastic properties of thyroid cancer cells.
Degl'Innocenti D; Romeo P; Tarantino E; Sensi M; Cassinelli G; Catalano V; Lanzi C; Perrone F; Pilotti S; Seregni E; Pierotti MA; Greco A; Borrello MG
Endocr Relat Cancer; 2013 Feb; 20(1):23-37. PubMed ID: 23132790
[TBL] [Abstract][Full Text] [Related]
30. Germline and somatic mutations of the RET proto-oncogene in apparently sporadic medullary thyroid carcinomas.
Scurini C; Quadro L; Fattoruso O; Verga U; Libroia A; Lupoli G; Cascone E; Marzano L; Paracchi S; Busnardo B; Girelli ME; Bellastella A; Colantuoni V
Mol Cell Endocrinol; 1998 Feb; 137(1):51-7. PubMed ID: 9607728
[TBL] [Abstract][Full Text] [Related]
31. Potent mitogenicity of the RET/PTC3 oncogene correlates with its prevalence in tall-cell variant of papillary thyroid carcinoma.
Basolo F; Giannini R; Monaco C; Melillo RM; Carlomagno F; Pancrazi M; Salvatore G; Chiappetta G; Pacini F; Elisei R; Miccoli P; Pinchera A; Fusco A; Santoro M
Am J Pathol; 2002 Jan; 160(1):247-54. PubMed ID: 11786418
[TBL] [Abstract][Full Text] [Related]
32. Oncogenes and thyroid cancer.
Vecchio G; Santoro M
Clin Chem Lab Med; 2000 Feb; 38(2):113-6. PubMed ID: 10834397
[TBL] [Abstract][Full Text] [Related]
33. M918V RET mutation causes familial medullary thyroid carcinoma: study of 8 affected kindreds.
Martins-Costa MC; Cunha LL; Lindsey SC; Camacho CP; Dotto RP; Furuzawa GK; Sousa MS; Kasamatsu TS; Kunii IS; Martins MM; Machado AL; Martins JR; Dias-da-Silva MR; Maciel RM
Endocr Relat Cancer; 2016 Dec; 23(12):909-920. PubMed ID: 27807060
[TBL] [Abstract][Full Text] [Related]
34. Distinct frequency of ret rearrangements in papillary thyroid carcinomas of children and adults from Belarus.
Smida J; Salassidis K; Hieber L; Zitzelsberger H; Kellerer AM; Demidchik EP; Negele T; Spelsberg F; Lengfelder E; Werner M; Bauchinger M
Int J Cancer; 1999 Jan; 80(1):32-8. PubMed ID: 9935226
[TBL] [Abstract][Full Text] [Related]
35. Single nucleotide polymorphisms act as modifiers and correlate with the development of medullary and simultaneous medullary/papillary thyroid carcinomas in 2 large, non-related families with the RET V804M proto-oncogene mutation.
Shifrin AL; Ogilvie JB; Stang MT; Fay AM; Kuo YH; Matulewicz T; Xenachis CZ; Vernick JJ
Surgery; 2010 Dec; 148(6):1274-80; discussion 1280-1. PubMed ID: 21134561
[TBL] [Abstract][Full Text] [Related]
36. The physical map of the human RET proto-oncogene.
Pasini B; Hofstra RM; Yin L; Bocciardi R; Santamaria G; Grootscholten PM; Ceccherini I; Patrone G; Priolo M; Buys CH
Oncogene; 1995 Nov; 11(9):1737-43. PubMed ID: 7478601
[TBL] [Abstract][Full Text] [Related]
37. [Somatic ret proto-oncogene mutations in sporadic C-cell carcinoma of the thyroid gland].
Frilling A; Bockhorn M; Kalinin V; Liedke M; Kaun M; Broelsch CE
Chirurg; 1997 Aug; 68(8):789-93. PubMed ID: 9377989
[TBL] [Abstract][Full Text] [Related]
38. Germline ESR2 mutation predisposes to medullary thyroid carcinoma and causes up-regulation of RET expression.
Smith J; Read ML; Hoffman J; Brown R; Bradshaw B; Campbell C; Cole T; Navas JD; Eatock F; Gundara JS; Lian E; Mcmullan D; Morgan NV; Mulligan L; Morrison PJ; Robledo M; Simpson MA; Smith VE; Stewart S; Trembath RC; Sidhu S; Togneri FS; Wake NC; Wallis Y; Watkinson JC; Maher ER; McCabe CJ; Woodward ER
Hum Mol Genet; 2016 May; 25(9):1836-45. PubMed ID: 26945007
[TBL] [Abstract][Full Text] [Related]
39. The RET/PTC3 oncogene: metastatic solid-type papillary carcinomas in murine thyroids.
Powell DJ; Russell J; Nibu K; Li G; Rhee E; Liao M; Goldstein M; Keane WM; Santoro M; Fusco A; Rothstein JL
Cancer Res; 1998 Dec; 58(23):5523-8. PubMed ID: 9850089
[TBL] [Abstract][Full Text] [Related]
40. Genetic testing for familial cancer. Consequences of RET proto-oncogene mutation analysis in multiple endocrine neoplasia, type 2.
Learoyd DL; Marsh DJ; Richardson AL; Twigg SM; Delbridge L; Robinson BG
Arch Surg; 1997 Sep; 132(9):1022-5. PubMed ID: 9301617
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
